Sign in to view content

MCO-010 Optogenetic Therapy for Severe Vision Loss in Stargardt Disease: 6-Month Outcomes From the Phase 2 STARLIGHT Trial

Allen C Ho, MD FASRS

Video
Published 2023

Related

Suprachoroidal Delivery of RGX-314 for Neovascular AMD Results of the Phase II AAVIATE Study
David S. Boyer, MD
Annual Meeting Talks
2023
A Multicenter Post-Authorization Safety Study of Patients Treated With Voretigene Neparvovec-rzyl Gene Therapy in the United States: Interim Analysis at 3 Years
Aaron Nagiel, MD, PhD
Annual Meeting Talks
2024
Subretinal Delivery of RGX-314: Gene Therapy for Neovascular Age-Related Macular Degeneration
Ashkan M. Abbey, MD, FASRS, FAAO
Annual Meeting Talks
2023

Category: Hereditary Retinal Disease & Genetics

See more